

1 **Text S1.**

2 **Plasmid Construction.** To generate pHERD20T-*wzz2*, the *wzz2* coding region was amplified  
3 using oAC017/oAC018 and the PCR product, along with pHERD20T, were digested using NcoI  
4 and HindIII (New England BioLabs). The *wzz2* fragment and digested pHERD20T were gel  
5 purified, ligated (New England BioLabs) in a 2:1 ratio, and the reaction was then transformed via  
6 heat-shock into chemically competent DH5 $\alpha$  (Invitrogen) and selected for resistance on  
7 carbenicillin. Plasmids were PCR verified using oAC039/oAC040 and sequence confirmed.

8 Construction of miniCTX1-P<sub>*wzz2*</sub>-optRBS-*lacZ* was accomplished by amplifying *lacZ*  
9 from miniCTX-*lacZ* using oJM524, which containing an consensus ribosome-binding site  
10 (taaggagg) (12), and oJM456. This PCR product, along with miniCTX1, was cut with PstI-  
11 HindIII (New England BioLabs) and ligated together to generate miniCTX1-optRBS-*lacZ*. Next,  
12 500 bps of the upstream *wzz2* promoter region was amplified using oAC053/oAC054 and  
13 inserted into HindIII digest miniCTX1-optRBS-*lacZ* using isothermal assembly (Gibson  
14 Assembly Master Mix, New England BioLabs) following the manufacturers protocol. The  
15 reactions were transformed into chemically competent DH5 $\alpha$  and selected for on the appropriate  
16 antibiotic. Plasmids were extracted from isolated colonies, PCR verified using oAC032/oAC033,  
17 and sequence verified. miniCTX1-P<sub>*wzz2*</sub>-optRBS-*lacZ* was electroporated into electrocompetent  
18 PAO1, PDO300, PDO300nmr1, and PAO1 *mucA22 amrZ::Tn* as previously described (15, 17) to  
19 generate PAO1 attCTX::<sub>*wzz2*</sub>-optRBS-*lacZ*, PDO300 attCTX::<sub>*wzz2*</sub>-optRBS-*lacZ*, PDO300nmr1  
20 attCTX::<sub>*wzz2*</sub>-optRBS-*lacZ*, and PAO1 *mucA22 amrZ::Tn* attCTX::<sub>*wzz2*</sub>-optRBS-*lacZ*.  
21 Insertions at the CTX site were verified using oAC056/oAC057.

22 In order to generate the inducible constructs miniTn7T-lacIq-Ptac-*amrZ* and miniTn7T-  
23 lacIq-Ptac-*algT* we amplified the coding sequence of *amrZ*, using oAC137/oAC138, or *algT*,

24 using oA221C/oAC222, from PAO1 using PCR. The amplified sequence was then inserted into  
25 HindIII digest miniTn7T-Gm-lacIq-P<sub>tac</sub> using isothermal assembly (Gibson Assembly Master  
26 Mix, New England BioLabs) following the manufacturers protocol. All reactions were  
27 transformed into chemically competent DH5 $\alpha$  and selected for on the appropriate antibiotic.  
28 Plasmids were extracted from isolated colonies, PCR verified using oAC148/oAC149, and  
29 sequence verified. miniTn7T-lacIq-P<sub>tac</sub>-*amrZ* was electroporated into electrocompetent PAO1  
30 attCTX::P<sub>wzz2</sub>-optRBS-*lacZ*, PDO300 attCTX::P<sub>wzz2</sub>-optRBS-*lacZ*, and PAO1 *mucA22 amrZ*::Tn  
31 attCTX::P<sub>wzz2</sub>-optRBS-*lacZ* as previously described (15, 17) to generate PAO1 attCTX::P<sub>wzz2</sub>-  
32 optRBS-*lacZ* attTn7::lacIq-P<sub>tac</sub>-*amrZ*, PDO300 attCTX::P<sub>wzz2</sub>-optRBS-*lacZ* attTn7::lacIq-P<sub>tac</sub>-  
33 *amrZ*, and PAO1 *mucA22 amrZ*::Tn attCTX::P<sub>wzz2</sub>-optRBS-*lacZ* attTn7::lacIq-P<sub>tac</sub>-*amrZ*.  
34 miniTn7T-lacIq-P<sub>tac</sub>-*algT* was electroporated into electrocompetent PAO1 attCTX::P<sub>wzz2</sub>-  
35 optRBS-*lacZ* and PDO300nmr1 attCTX::P<sub>wzz2</sub>-optRBS-*lacZ* to generate PAO1 attCTX::P<sub>wzz2</sub>-  
36 optRBS-*lacZ* attTn7::lacIq-P<sub>tac</sub>-*algT*, and PDO300nmr1 attCTX::P<sub>wzz2</sub>-optRBS-*lacZ*  
37 attTn7::lacIq-P<sub>tac</sub>-*algT*. 500 ng of pTNS3 helper plasmid was also included when transforming  
38 miniTn7T vectors. Insertions at the Tn7 site were verified using oAC129/oAC130.

39 To generate pEXG2-*mucA22* the *mucA22* allele was PCR amplified from PDO300 using  
40 oAC089/oAC090 and inserted into HindIII digest pEXG2 using isothermal assembly (Gibson  
41 Assembly Master Mix, New England BioLabs) following the manufacturers protocol. The  
42 reactions were transformed into chemically competent DH5 $\alpha$  and selected for on the appropriate  
43 antibiotic. Plasmids were extracted from isolated colonies, PCR verified using primers  
44 oAC091/oAC092, and sequence verified.

45 To overexpress *wzz2* in order to generate polyclonal antibody the *wzz2* coding region  
46 from nucleotides 150-1173 (to exclude transmembrane sequences in the first and last 150 bps of

47 the gene) was PCR amplified from *P. aeruginosa* strain PA103 using primers oJM483/oJM484  
48 and cloned into pET28a digested with NdeI-XhoI (New England BioLabs) by isothermal  
49 assembly to construct pET28a-his6-*wzz2deltaTMS*. The Wzz2 N-terminus contains a 6X His-tag.

50

51 **Generation of Wzz2 polyclonal antibodies.** *E. coli* BL21(DE3) containing pET28a-his6-  
52 *wzz2deltaTMS* was induced with 0.2 mM IPTG at 16°C overnight in a 2.8 L Fernbach flask  
53 containing 1 L LB containing kanamycin. Cells were then lysed using a French press and protein  
54 was purified first by a nickel column and then by size exclusion (HiLoad16/60 Superdex200  
55 FPLC). Purified Wzz2 was sent to and used by Covance (Princeton, NJ) to generate polyclonal  
56 antibodies in White New Zealand Rabbits.

57

58 **Western blot analysis.** Protein and LPS samples were thawed at room temperature, boiled for 5  
59 minutes, and then cooled to room temperature. Proteins were separated by 10% SDS-PAGE and  
60 LPS was separated by 12% SDS-PAGE (Bio-Rad). Both were transferred to a polyvinylidene  
61 difluoride membrane (PVDF, Bio-Rad). The membranes were blocked in PBS-T containing 5%  
62 instant nonfat dry milk (Publix) and probed using specific polyclonal antibodies for O5 serotype  
63 antigen (1:2,500, Denka Seiken Co. Ltd. Group B), O10 serotype antigen (1:5,000 Denka Seiken  
64 Co. Ltd. Group H) Wzz2 (1:10,000), or a monoclonal antibody for EF-Tu (1:10,000, LS Bio)  
65 followed by a 1:10,000 dilution of horseradish peroxidase-conjugated anti-rabbit IgG (O5  
66 antigen, O10 antigen, and Wzz2) or anti-mouse IgG (EF-Tu) immunoglobulin antibody (Sigma-  
67 Aldrich). Detection was performed using Pierce ECL Western Blotting Substrate (following  
68 manufacturer's instructions) and chemiluminescence detection. Images were obtained using a  
69 ChemiDoc Imaging System (Bio-Rad) and densitometry analyzed was performed using Image

70 Lab volume 5.2.1 software (Bio-Rad) relative quantity tool.

71

72 **qRT-PCR.** 500  $\mu$ l of exponential phase culture was added to 1 ml of RNA Protect (Qiagen),  
73 incubated at room temperature for 5 minutes, and then centrifuged at 5,000 x g for 10 minutes.  
74 Pellets were air-dried and stored at -80°C. Total RNA was extracted using the MasterPure RNA  
75 Purification Kit (Epicentre) following the manufacturers protocol and 10  $\mu$ g of total RNA was  
76 converted into cDNA using the SuperScript III First-Strand Synthesis System Kit (Invitrogen)  
77 following the manufacturer's instructions. Random hexamers were used to convert 1  $\mu$ g of RNA  
78 to cDNA. Finally, cDNA was used to perform qPCR using *wzz2* specific primers  
79 oAC001/oAC002 and Fast Start Universal SybrGreen Master Mix (Roche) for detection. The  
80 amount of *wzz2* expressed was quantified based on cycle threshold ( $C_T$ ) and primer efficiencies  
81 were determined using a standard curve of purified genomic DNA. All samples were then  
82 normalized to the housekeeping gene *rpoD* that was detected using oAC003/oAC004.

83

84 **Alginate isolation and quantification.** Single colonies were used to inoculate 3 ml LB and  
85 allowed to grow, rolling at 37°C, until turbid. This culture was back-diluted to an  $OD_{600}$  of 0.01  
86 into 20 ml LB and allowed to grow overnight at 37°C, shaking. 10 ml of overnight culture was  
87 combined with 10 ml of 0.85% sodium chloride (Sigma) in a 50 ml conical tube, vortexed, and  
88 centrifuged at 12,000 x g for 30 minutes to remove cell material. The supernatant was transferred  
89 to a clean 50 ml conical tube and combined with 20 ml of 2% cetyl pyridinium (ACROS  
90 Organics), inverted 10 times to precipitate the alginate, and then centrifuged for at 12,000 x g for  
91 10 minutes. The supernatant was carefully poured off of the pellet and discarded. The alginate  
92 pellet was resuspended in 10 ml of 1 M sodium chloride, vortexed thoroughly, a pipet was used

93 to break up the pellet, and then incubated at room temperature for 30 minutes to ensure pellet had  
94 gone into solution. 10 ml of isopropanol (Fisher Scientific) was added to the solution, inverted  
95 10 times to reprecipitate the alginate, vortexed thoroughly, and then the solution was centrifuged  
96 again at 12,000 x g for 10 minutes. The supernatant was carefully poured off of the clear alginate  
97 pellet and a pipet was used to remove any residual isopropanol. Finally, the alginate pellet was  
98 resuspended in 10 ml 0.85% sodium chloride and a pipet was used to break up the pellet. Final  
99 suspension was incubated at 4°C overnight.

100           Alginate was quantified by heating at 55°C in a borate-carbazole solution. All values  
101 were compared to a standard curve generated by diluting laboratory grade alginic acid (Sigma) in  
102 0.85% sodium chloride to concentrations of 100-900 ug/ml. Briefly, 6 µl of purified alginate or  
103 standard was added to 200 µl of 0.1 M H<sub>3</sub>BO<sub>3</sub> reagent (created by adding 5 ml of 2 M BO<sub>3</sub><sup>-3</sup>  
104 added to 95 ml of ACS- grade H<sub>2</sub>SO<sub>4</sub>). The 2 M BO<sub>3</sub><sup>-3</sup> stock was created by adding 24.74g  
105 H<sub>3</sub>BO<sub>3</sub> to 45 ml 4 M KOH, with heat, and then diluted to 200 ml in water. Next, 6 µl of 0.1%  
106 carbazole reagent (Sigma) was added and this solution was incubated at 55°C for 30 minutes in a  
107 water bath to allow for sufficient purple color to develop. After incubation, the solution was  
108 mixed and transferred to a 96-well plate. Absorbance was measured at 530 nm in a BioTek  
109 Synergy H1M plate reader and values were compared to the standard curve generated.